Across 4 studies, all reported beneficial effects of Bifidobacterium animalis subsp. lactis BB-12 on short-chain fatty acid production, with effect sizes ranging from small to moderate. One meta-analysis in older adults found small beneficial effects on valeric acid (SMD = 0.50) and acetic acid (SMD = 0.62), while two in vitro studies showed moderate increases in SCFA levels. Doses, forms, and study durations were not consistently reported, limiting precise characterization. Most evidence comes from heterogeneous study designs (meta-analysis, in vitro experiments) rather than consistent human trials.
Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 4 studies) — conclusions should be considered preliminary. Only one of the four studies reported statistical significance, and two studies lack clear population or sample size data. The only human data comes from a meta-analysis that included synbiotics (not probiotic alone), making it difficult to isolate the specific effect of BB-12. Most studies used in vitro or processing methods, not direct supplementation trials in humans.
Synbiotic supplementation enhanced valeric acid (SMD = 0.50) and acetic acid levels (SMD = 0.62)
Both processing methods significantly increased SCFA levels (p < 0.05).
Higher contents of lactate, acetate, and butyrate and higher amylase activity were observed in RS5 compared to RS2 after fermentation.
Both synbiotic yogurts increased levels of beneficial organic acids, such as propionate and lactate, and decreased ammonium ion concentrations
levels of acetate, propionate, and butyrate were significantly elevated in fecal samples